| 摘要 |
The pharmaceutical compsn. comprises an active benzodiazepine, dibenzothiepine or quinolinylmethanol deriv. dispersed in an aq. liposome soln. (pref., a monolamellar liposome of diam. 25-200 nm) contg. a sugar or related polyol (at least 0.4 mol/dm3), which is opt. freeze-dried. Pref., active components are 1-methyl-5phenyl-7- chloro-1,3-dihydro-2H-benzodiazepine-2-one, erythro-alpha 2- piperidyl-2,8-bis(trifluoromethyl)quinonine-4-yl-methanol and their nontoxic salts. The liposome content reduces undesirable side effects.
|
